Trial Profile
Double-Blind, Randomized, Placebo-Controlled, Multi-Center Phase 3 Study to Evaluate the Efficacy and Safety of Fostamatinib in COVID-19 Subjects
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 30 Jan 2024
Price :
$35
*
At a glance
- Drugs Fostamatinib (Primary)
- Indications COVID 2019 infections
- Focus Registrational; Therapeutic Use
- Acronyms FOCUS
- Sponsors Rigel Pharmaceuticals
- 11 Oct 2023 According to a Rigel Pharmaceuticals media release, the company announced an upcoming oral presentation highlighting data from the FOCUS Phase 3 clinical trial at IDWeek 2023 being held October 11-15, 2023, in Boston, MA.
- 13 Apr 2023 Last checked against ClinicalTrials.gov record.
- 07 Apr 2023 Status changed from active, no longer recruiting to completed.